About inclisiran
Inclisiran manufacturers are currently limited to the originator, Novartis, which sells it as Leqvio. Inclisiran is a small interfering RNA (siRNA) that lowers LDL cholesterol by silencing the PCSK9 gene in the liver. It is injected under the skin twice a year after two initial doses, which makes it one of the least frequently dosed cholesterol treatments. No generic is approved. Companies interested in inclisiran can explore future generic development or oligonucleotide manufacturing partnerships.
Inclisiran key facts
|
Property |
Inclisiran |
|---|---|
|
INN |
Inclisiran (as sodium) |
|
Molecule type |
Chemically modified double-stranded siRNA conjugated to GalNAc (liver targeting) |
|
ATC code |
C10AX16 |
|
Drug class |
PCSK9 siRNA; lipid-lowering agent |
|
Brand name |
Leqvio |
|
Originator |
Developed with Alnylam technology by The Medicines Company; acquired by Novartis in 2020 |
|
Dosage form and strength |
Solution for subcutaneous injection, 284 mg in prefilled syringe |
|
Dose |
284 mg at day 0, month 3, then every 6 months |
|
Indications |
Primary hypercholesterolaemia and mixed dyslipidaemia, to lower LDL cholesterol, with diet and other lipid-lowering therapy as appropriate |
|
First approval |
EU, December 2020 |
|
US approval |
FDA, December 2021 |
|
Generic status |
None approved |
Inclisiran manufacturers and licensing history
Inclisiran was developed by The Medicines Company using Alnylam's RNA interference technology. Novartis acquired The Medicines Company in January 2020. The EU approved Leqvio in December 2020, and the FDA in December 2021.
Inclisiran works by a different mechanism from statins and PCSK9 antibodies. Because it is given only twice a year by a healthcare professional, it can help patients who struggle with daily tablets or frequent injections. Novartis has since broadened its use and is running cardiovascular outcomes studies.
No generic inclisiran is approved. Generic developers would need oligonucleotide synthesis and GalNAc conjugation capability. Buyers should confirm manufacturing capability, impurity control and freedom to operate.
Inclisiran dosage forms and dossier types
Inclisiran is supplied as a 284 mg solution for subcutaneous injection in a single-dose prefilled syringe.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
Inclisiran injection |
284 mg/1.5 ml prefilled syringe |
Future US ANDA; EU CTD |
Reference Leqvio |
|
Inclisiran drug substance |
Bulk |
Future DMF |
Oligonucleotide synthesis and GalNAc conjugation |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
United States |
Future ANDA |
Patents and exclusivities |
|
European Union |
Future EU CTD |
Data protection and SPC expiry |
|
Other markets |
CTD |
Check local patents |
Inclisiran regulatory and patent status
The EU approved inclisiran in December 2020, and the FDA in December 2021. It is protected by patents and regulatory exclusivities, and no generic is approved. Check national patent registers before planning development.
Inclisiran mechanism of action and therapeutic use
Inclisiran enters liver cells through the GalNAc receptor and uses RNA interference to destroy the messenger RNA for PCSK9. With less PCSK9, more LDL receptors stay on the liver cell surface and remove LDL cholesterol from the blood. Inclisiran is injected by a healthcare professional at the start, after 3 months and then every 6 months, usually alongside a statin.
Inclisiran licensing and sourcing
Inclisiran is currently available only from Novartis. Companies interested in this molecule usually prepare future generic dossiers or oligonucleotide manufacturing partnerships. Current offers and supplier contacts are listed among the inclisiran manufacturers on Pipelinepharma.
Frequently asked questions about inclisiran
Who manufactures inclisiran? Novartis is the only manufacturer and sells inclisiran as Leqvio.
How often is inclisiran given? Inclisiran is injected at the start, after 3 months and then every 6 months.
What is inclisiran used for? Inclisiran is used to lower LDL cholesterol in adults with hypercholesterolaemia or mixed dyslipidaemia.
Is there a generic version of inclisiran? No. No generic inclisiran is approved.
How is inclisiran different from PCSK9 antibodies? PCSK9 antibodies, such as evolocumab, block PCSK9 in the blood every 2–4 weeks. Inclisiran stops PCSK9 being made in the liver and is given twice a year.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.